肺癌患者血浆中基质金属蛋白酶抑制剂2蛋白水平及其临床意义

doi:10.3969/j.issn.1004-616x.2013.03.013

Abstract

Abstract:

OBJECTIVE: To detect the plasma protein levels of tissue inhibitor of metalloproteinases 2 (TIMP2) in lung cancer patients and healthy controls，and analyze its clinical significance. METHODS：Plasma TIMP2 level in 114 patients with primary lung cancer and 100 healthy subjects were measured by an enzyme immunoassay (ELISA). RESULTS：The plasma level of TIMP2 in patients with primary lung cancer (74.56±16.70) ng/mL was significantly lower than the healthy controls (170.98±48.61) ng/mL (P<0.01). The TIMP2 level in stage Ⅲ+Ⅳ(81.57±15.62) ng/mL were significantly higher than those in stage Ⅰ+Ⅱ(69.16±15.63) ng/mL (P<0.01). The plasma TIMP2 levels were elevated in the patients with tumor >3 cm (P<0.01)，and correlated with distant metastasis (P<0.01). When the TIMP2 cutoff value was set to 103.29 ng/mL，sensitivity of lung cancer detection was 97.4%， and specificity was 82.8%. CONCLUSION：Measurement of plasma level of TIMP2 protein may contribute to the diagnosis of lung cancer.

Key words: lung cancer, tissue inhibitor of metalloproteinases 2, enzyme linked immunosorbent assay, plasma, tumor marker

YANG Lei，WU Yong-kai，HAN Nai-jun，SUN Ke-lin，CHENG Shu-jun，GAO Yan-ning，XIAO Ting. TIMP2 plasma protein level and its clinical significance in lung cancer patients[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2013.03.013.

References

[1] Cersosimo RJ. Lung cancer：a review[J]. Am J Health Syst Pharm，2002，59 (7)：611-642.

[2] Martin J，Ginsberg RJ，Venkatraman ES，et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer[J]. J Clin Oncol，2002，20 (8)：1989-1995.

[3] Xiao T，Ying WT，Li L，et al. An approach to studying lung cancer-related proteins in human blood[J]. Mol Cell Proteomics， 2005，4 (10)：1480-1486.

[4] Jiang Y，Goldberg ID，Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer[J]. Oncogene，2002，21 (14)： 2245-2252.

[5] Pennanen H，Kuittinen O，Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma[J]. Eur J Haematol，2008，80 (1)：46-54.

[6] Peterson NB，Beeghly-Fadiel A，Gao YT，et al. Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival[J]. Int J Cancer，2009，125 (4)：844-850.

[7] Zhang Y，Xu B，Liu Y，et al. The ovarian cancer-derived secretory/releasing proteome：A repertoire of tumor markers[J]. Proteomics，2012，12 (11)：1883-1891.

[8] Nuttall RK，Sampieri CL，Pennington CJ，et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development[J]. FEBS Lett，2004，563 (1/2/3)：129-134.

[9] Kessenbrock K，Plaks V，Werb Z. Matrix metalloproteinases： regulators of the tumor microenvironment[J]. Cell，2010，141 (1)：52-67.

[10] Pennanen H，Kuittinen O，Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma[J]. Eur J Haematol，2008，80 (1)：46-54.

[11] Cruz-Munoz W，Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis[J]. Crit Rev Clin Lab Sci，2008，45 (3)：291-338.

[12] Li H，Lindenmeyer F，Grenet C，et al. AdTIMP-2 inhibits tumor growth，angiogenesis，and metastasis，and prolongs survival in mice[J]. Hum Gene Ther，2001，12 (5)：515-526.

[13] Guedez L，Jensen-Taubman S，Bourboulia D，et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis[J]. J Immunother， 2012，35 (6)：502-512.

[1]	YANG Liyan, LIU Zou, HAO Jiajie, ZHANG Yu, WANG Mingrong. Study on the mechanism of nucleo-plasma translocation of p62 protein in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 338-344.
[2]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[3]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[4]	ZHAO Junwei, HUA Chenfeng, SHANG Pingping, XIE Fuwei, LI Xiang. Induction of oxidative stress by arsenious acid As(Ⅲ) in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 28-31.
[5]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.
[6]	ZHANG Fan, LIU Guangchao, ZHANG Zhihan, LIU Fangfang, XIE Qi, GAO Shuqing. Effect of ketogenic diet on growth of subcutaneously transplanted human lung cancer in nude mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 286-291.
[7]	YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.
[8]	MA Ming, JIAO Wenjing, WANG Yanhai, YAN Xi, ZHANG Chao, ZHANG Jinyan. Clinical values of serum IL-24 and IL-6 concentrations for patients with diffuse large B-cell lymphoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 227-230.
[9]	ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting. Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 89-95.
[10]	WU Wen, LI Ping, ZUO Ran, ZENG Qingbo, WU Desheng, XIE Ni, LONG Dingxin, YUAN Jianhui. Correlation between polymorphism of DNA methyltransferase 3B-149C>T and cancer risk:a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 102-110.
[11]	WU Yilan, WANG Han. Inhibition of proliferation by resveratrol in paclitaxel-resistant lung adenocarcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 200-203,208.
[12]	MA Bangjing, HAO Xianglin, HAN Fei, CHEN Hongqiang, LIU Jinyi, CAO Jia, ZHANG Aihua. Inhibition of proliferation and migration of lung adenocarcinoma cells by SOX30 gene via regulation of DSC3 gene [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 165-170,175.
[13]	PENG Hui, MA Shumei, HONG Weiwei, SUI Jing, ZHANG Yanqiu, LIANG Geyu. Regulatory mechanism of miR-202 on proliferation of A549 lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 454-459.
[14]	ZHANG Jing, TENG Yu, ZHAO Xiaoting, JIANG Mei, YUE Wentao. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 245-250.
[15]	LIU Fuzhi, LI Hongtu, WU Chuancheng, CAI Ailan, CHEN Yu, LIU Baoying. A case control study on presence of chemical elements in plasma of gastric cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(3): 230-234.

TIMP2 plasma protein level and its clinical significance in lung cancer patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments